Magnetic iron oxide nanoparticles as drug carriers: clinical relevance

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Wu W, Jiang CZ, Roy VAL. Designed synthesis and surface engineering strategies of magnetic iron oxide nanoparticles for biomedical applications. Nanoscale 8(47), 19421–19474 (2016). •• Excellent review with an overview of the use of MNPs for biomedical applications.
  Medline CASGoogle Scholar
• 2 Laurent S, Saei AA, Behzadi S, Panahifar A, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin. Drug Deliv. 11(9), 1449–1470 (2014).
  Medline CASGoogle Scholar
• 3 Wahajuddin M, Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int. J. Nanomedicine 7, 3445–3471 (2012).
  Medline CASGoogle Scholar
• 4 Prijic S, Sersa G. Magnetic nanoparticles as targeted delivery systems in oncology. Radiol. Oncol. 45, 1–16 (2011). • Review with an overview of the use of different types of NPs as targeted delivery in oncology.
  Medline CASGoogle Scholar
• 5 Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today 2(3), 22–32 (2007). • Sound discussions about the use of MNPs for drug delivery.
  Google Scholar
• 6 Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320–368 (2009).
  Medline CASGoogle Scholar
• 7 National Cancer Institute. Types of treatment (2017). www.cancer.gov/.
  Google Scholar
• 8 Jackson SE, Chester JD. Personalised cancer medicine. Int. J. Cancer 137, 262–266 (2015).
  Medline CASGoogle Scholar
• 9 Schork NJ. Personalized medicine: time for one-person trials. Nature 520, 609–611 (2015).
  Medline CASGoogle Scholar
• 10 Bañobre-López M, Teijeiro A, Rivas J. Magnetic nanoparticle-based hyperthermia for cancer treatment. Rep. Pract. Oncol. Radiother. 18(6), 397–400 (2013).
  MedlineGoogle Scholar
• 11 Kumar CSSR, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv. Drug Deliv. Rev. 63, 789–808 (2011).
  Medline CASGoogle Scholar
• 12 Kumar CSSR, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv. Drug Deliv. Rev. 63(9), 789–808 (2011).
  Medline CASGoogle Scholar
• 13 Chatterjee DK, Diagaradjane P, Krishnan S. Nanoparticle-mediated hyperthermia in cancer therapy. Ther. Deliv. 2(8), 1001–1014 (2011).
  Medline CASGoogle Scholar
• 14 Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer 14(3), 199 (2014).
  Medline CASGoogle Scholar
• 15 Yoo D, Jeong H, Noh S-H, Lee J-H, Cheon J. Magnetically triggered dual functional nanoparticles for resistance-free apoptotic hyperthermia. Angew. Chem. Int. Ed. 52, 13047–13051 (2013).
  Medline CASGoogle Scholar
• 16 Salunkhe AB, Khot VM, Pawar SH. Magnetic hyperthermia with magnetic nanoparticles: a status review. Curr. Top. Med. Chem. 14(5), 572–594 (2014).
  Medline CASGoogle Scholar
• 17 Jeon MJ, Ahn C-H, Kim H et al. The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model. J. Exp. Clin. Cancer Res. 33(1), 57 (2014).
  MedlineGoogle Scholar
• 18 Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. Nano Life 1, 10 (2010).
  Google Scholar
• 19 Obaidat IM, Issa B, Haik Y. Magnetic properties of magnetic nanoparticles for efficient hyperthermia. Nanomaterials 5(1), 63–89 (2015).
  MedlineGoogle Scholar
• 20 Jun Y-W, Lee J-H, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew. Chem. Int. Ed. 47(28), 5122–5135 (2008). •• Excellent review about the use of MNPs for MRI.
  Medline CASGoogle Scholar
• 21 Revia RA, Zhang M. Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances. Materials Today 19, 157–168 (2016).
  Medline CASGoogle Scholar
• 22 Krukemeyer MG, Krenn V, Jakobs M, Wagner W. Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets − sarcoma treatment in progress. J. Drug Target. 20(2), 185–193 (2012).
  Medline CASGoogle Scholar
• 23 Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 70, 7553–7561 (2010).
  Medline CASGoogle Scholar
• 24 Krukemeyer MG, Krenn V, Jakobs M, Wagner W. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver-magnetic nanoparticles in cancer treatment. J. Surg. Res. 175, 35–43 (2012).
  Medline CASGoogle Scholar
• 25 Li Z, Dong K, Huang S et al. A smart nanoassembly for multistage targeted drug delivery and magnetic resonance imaging. Adv. Funct. Mater. 24(23), 3612–3620 (2014).
  CASGoogle Scholar
• 26 Muthana M, Kennerley AJ, Hughes R et al. Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. Nat. Commun. 6, 8009 (2015).
  Medline CASGoogle Scholar
• 27 Sanson C, Diou O, Thévenot J et al. Doxorubicin loaded magnetic polymersomes: theranostic nanocarriers for MR imaging and magneto-chemotherapy. ACS Nano 5(2), 1122–1140 (2011).
  Medline CASGoogle Scholar
• 28 Chang P, Purushotham S, Rumpel H et al. Novel dual magnetic drug targeting and hyperthermia therapy in hepatocellular carcinoma with thermosensitive polymer-coated nanoparticles. J. Gastroint. Dig. Syst. 4, 198 (2014).
  Google Scholar
• 29 Hayashi K, Nakamura M, Miki H et al. Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release. Theranostics 4(8), 834–844 (2014).
  MedlineGoogle Scholar
• 30 Maier-Hauff K, Ulrich F, Nestler D et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 103(2), 317–324 (2011).
  MedlineGoogle Scholar
• 31 Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271–284 (2000).
  Medline CASGoogle Scholar
• 32 Hobbs SK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607–4612 (1998).
  Medline CASGoogle Scholar
• 33 Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano 7, 7442–7447 (2013). •• Signature article discussing the myths and reality of drug delivery.
  Medline CASGoogle Scholar
• 34 Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release 153(3), 198–205 (2011). •• Signature article discussing the myths and reality of targeted delivery to tumors.
  Medline CASGoogle Scholar
• 35 Leamon CP, Cooper SR, Hardee GE. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjugate Chem. 14(4), 738–747 (2003).
  Medline CASGoogle Scholar
• 36 El-Boubbou K, Ali R, Bahhari HM et al. Magnetic fluorescent nanoformulation for intracellular drug delivery to human breast cancer, primary tumors, and tumor biopsies: beyond targeting expectations. Bioconjugate Chem. 27(6), 1471–1483 (2016).
  Medline CASGoogle Scholar
• 37 Ryppa C, Mann-Steinberg H, Fichtner I et al. In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin αvβ3. Bioconjugate Chem. 19(7), 1414–1422 (2008).
  Medline CASGoogle Scholar
• 38 Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6(5), 1949 (2000).
  Medline CASGoogle Scholar
• 39 Olson ES, Jiang T, Aguilera TA et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl Acad. Sci. 107, 4311–4316 (2010).
  Medline CASGoogle Scholar
• 40 Kirpotin DB, Drummond DC, Shao Y et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732–6740 (2006).
  Medline CASGoogle Scholar
• 41 Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control Release 148, 135–146 (2010).
  Medline CASGoogle Scholar
• 42 Tiwari G, Tiwari R, Sriwastawa B et al. Drug delivery systems: an updated review. Int. J. Pharm. Investig. 2(1), 2–11 (2012).
  MedlineGoogle Scholar
• 43 Cheng R, Meng F, Deng C, Klok H-A, Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 34, 3647–3657 (2013).
  Medline CASGoogle Scholar
• 44 Peng M, Li H, Luo Z et al. Dextran-coated superparamagnetic nanoparticles as potential cancer drug carriers in vivo. Nanoscale 7(25), 11155–11162 (2015).
  Medline CASGoogle Scholar
• 45 Kossatz S, Grandke J, Couleaud P et al. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. Breast Cancer Res. 17(1), 66 (2015).
  MedlineGoogle Scholar
• 46 Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 3, 703–717 (2008).
  CASGoogle Scholar
• 47 Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmaceut. 5, 505–515 (2008).
  Medline CASGoogle Scholar
• 48 Li S-D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5, 496–504 (2008). • Review giving valuable information about pharmacokinetics and biodistribution of NPs.
  Medline CASGoogle Scholar
• 49 Chauhan VP, Stylianopoulos T, Martin JD et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nano 7(6), 383–388 (2012).
  Medline CASGoogle Scholar
• 50 Tang L, Yang X, Yin Q et al. Investigating the optimal size of anticancer nanomedicine. Proc. Natl Acad. Sci. USA 111(43), 15344–15349 (2014).
  Medline CASGoogle Scholar
• 51 Peng XH, Qian X, Mao H et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int. J. Nanomed. 3, 311–321 (2008).
  Medline CASGoogle Scholar
• 52 Park J-H, Von Maltzahn G, Zhang L et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20(9), 1630–1635 (2008).
  Medline CASGoogle Scholar
• 53 Park S-J, Kim S, Lee S, Khim ZG, Char K, Hyeon T. Synthesis and magnetic studies of uniform iron nanorods and nanospheres. J. Am. Chem. Soc. 122(35), 8581–8582 (2000).
  CASGoogle Scholar
• 54 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotech. 2, 751–760 (2007).
  Medline CASGoogle Scholar
• 55 Laurent S, Saei AA, Behzadi S, Panahifar A, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin. Drug Deliv. 11, 1449–1470 (2014).
  Medline CASGoogle Scholar
• 56 Gaucher G, Asahina K, Wang J, Leroux J-C. Effect of Poly(N-vinyl-pyrrolidone)-block-poly(d,l-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules 10(2), 408–416 (2009).
  Medline CASGoogle Scholar
• 57 Laurent S, Forge D, Port M et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108(6), 2064–2110 (2008).
  Medline CASGoogle Scholar
• 58 Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28–51 (2016).
  Medline CASGoogle Scholar
• 59 Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83, 601–606 (1994).
  Medline CASGoogle Scholar
• 60 Tang BC, Dawson M, Lai SK et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl Acad. Sci. 106(46), 19268–19273 (2009).
  Medline CASGoogle Scholar
• 61 Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13(9), 655–672 (2014).
  Medline CASGoogle Scholar
• 62 Mitragotri S, Anderson DG, Chen X et al. Accelerating the translation of nanomaterials in biomedicine. ACS Nano 9(7), 6644–6654 (2015).
  Medline CASGoogle Scholar
• 63 Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat. Nano 3(5), 242–244 (2008).
  Medline CASGoogle Scholar
• 64 Markovsky E, Baabur-Cohen H, Eldar-Boock A et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J. Control Release 161(2), 446–460 (2012).
  Medline CASGoogle Scholar
• 65 Jin-Wook Y, Elizabeth C, Samir M. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 16(21), 2298–2307 (2010).
  MedlineGoogle Scholar
• 66 Barlas S. FDA strategies to prevent and respond to drug shortages: finding a better way to predict and prevent company closures. Pharm. Ther. 38, 261 (2013).
  Google Scholar
• 67 Smith JA, Costales AB, Jaffari M et al. Is it equivalent? Evaluation of the clinical activity of single agent Lipodox^® compared to single agent Doxil^® in ovarian cancer treatment. J. Oncol. Pharm. Pract. 22(4), 599–604 (2015).
  MedlineGoogle Scholar
• 68 Hrkach J, Von Hoff D, Ali MM et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128ra139 (2012).
  Google Scholar
• 69 Anselmo AC, Mitragotri S. A chemical engineering perspective of nanoparticle-based targeted drug delivery: a unit process approach. AIChE Journal 62(4), 966–974 (2016).
  CASGoogle Scholar
• 70 Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 4(11), 6303–6317 (2010).
  Medline CASGoogle Scholar
• 71 Zuckerman JE, Gritli I, Tolcher A et al. Correlating animal and human Phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl. Acad. Sci. USA 111(31), 11449–11454 (2014).
  Medline CASGoogle Scholar
• 72 Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine 12(1), 81–103 (2016).
  Medline CASGoogle Scholar
• 73 Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr. Opin. Biotechnol. 22(4), 492–501 (2011).
  Medline CASGoogle Scholar
• 74 Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng. Translat. Med. 1(1), 10–29 (2016). •• Excellent review giving an overview about various types of NPs used in the clinic.
  MedlineGoogle Scholar
• 75 Pillai G. Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. Pharm. Pharm. Sci. 1, 13 (2014).
  Google Scholar
• 76 Sievers EL, Senter PD. Antibody–drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15–29 (2013).
  Medline CASGoogle Scholar
• 77 Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41(7), 2971–3010 (2012).
  Medline CASGoogle Scholar
• 78 Wickham T, Futch K. A Phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive breast cancer. Cancer Res. 72(Suppl. 24), P5–18–09 (2012).
  Google Scholar
• 79 Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783–1791 (2012).
  Medline CASGoogle Scholar
• 80 Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320–368 (2009).
  Medline CASGoogle Scholar
• 81 Hahn PF, Stark DD, Lewis JM et al. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 175(3), 695–700 (1990).
  Medline CASGoogle Scholar
• 82 Oksendal AN, Bach-Gansmo T, Jacobsen TF, Eide H, Andrew E. Oral magnetic particles: results from clinical Phase II trials in 216 patients. Acta Radiol. 34, 187–193 (1993).
  Medline CASGoogle Scholar
• 83 Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur. Radiol. 13(6), 1266–1276 (2003).
  MedlineGoogle Scholar
• 84 Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11, 2319–2331 (2001).
  Medline CASGoogle Scholar
• 85 Michel SCA, Keller TM, Fröhlich JM et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 225(2), 527–536 (2002).
  MedlineGoogle Scholar
• 86 Trivedi RA, Mallawarachi C, U-King-Im J-M et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler. Thromb. Vasc. Biol. 26(7), 1601 (2006).
  Medline CASGoogle Scholar
• 87 Bachmann R, Conrad R, Kreft B et al. Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan^® (NC100150) for MRI of renal perfusion: experimental study in an animal model. J. Magn. Reson. Imaging 16(2), 190–195 (2002).
  MedlineGoogle Scholar
• 88 Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging 13(5), 661–674 (1995).
  Medline CASGoogle Scholar
• 89 Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging 13(5), 675–691 (1995).
  Medline CASGoogle Scholar
• 90 Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant. Imaging Med. Surg. 1(1), 35–40 (2011).
  MedlineGoogle Scholar
• 91 Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc. Chem. Res. 44, 842–852 (2011).
  Medline CASGoogle Scholar
• 92 Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical translation of nanomedicine. Chem. Rev. 115(19), 11147–11190 (2015).
  Medline CASGoogle Scholar
• 93 Thill M, Kurylcio A, Welter R et al. The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast 23(2), 175–179 (2014).
  MedlineGoogle Scholar
• 94 Winter A, Woenkhaus J, Wawroschek F. A novel method for intraoperative sentinel lymph node detection in prostate cancer patients using superparamagnetic iron oxide nanoparticles and a handheld magnetometer: the initial clinical experience. Ann. Surg. Oncol. 21(13), 4390–4396 (2014).
  MedlineGoogle Scholar
• 95 Freeman MW, Arrot A, Watson HHL. Magnetism in medicine. J. Appl. Phys. 31, S404 (1960).
  Google Scholar
• 96 Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur. J. Cancer Clin. Oncol. 19(1), 135–139 (1983).
  Medline CASGoogle Scholar
• 97 Lübbe AS, Bergemann C, Huhnt W et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 56(20), 4694–4701 (1996).
  Medline CASGoogle Scholar
• 98 Lübbe AS, Bergemann C, Riess H et al. Clinical experiences with magnetic drug targeting: a Phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56(20), 4686–4693 (1996).
  Medline CASGoogle Scholar
• 99 Alexiou C, Arnold W, Klein RJ et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60(23), 6641–6648 (2000).
  Medline CASGoogle Scholar
• 100 Alexiou C, Schmid RJ, Jurgons R et al. Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J. 35(5), 446–450 (2006).
  Medline CASGoogle Scholar
• 101 Goodwin S, Peterson C, Hoh C, Bittner C. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy. J. Magn. Magn. Mater. 194(1–3), 132–139 (1999).
  CASGoogle Scholar
• 102 Goodwin SC, Bittner CA, Peterson CL, Wong G. Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol. Sci. 60, 177–183 (2001).
  Medline CASGoogle Scholar
• 103 Koda J, Venook A, Walser E. A multicenter, Phase I/II trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocellular carcinoma. Eur. J. Cancer 38, S18 (2002).
  MedlineGoogle Scholar
• 104 Wilson MW, Kerlan RK, Fidelman NA et al. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite – initial experience with four patients. Radiology 230(1), 287–293 (2004).
  MedlineGoogle Scholar
• 105 Jahnke A, Hirschberger J, Fischer C et al. Intra-tumoral gene delivery of feil-2, feIFN-γ and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a Phase-I study. J. Vet. Med. A 54(10), 599–606 (2007).
  CASGoogle Scholar
• 106 Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB. Selective inductive heating of lymph nodes. Ann. Surg. 146(4), 596–606 (1957).
  Medline CASGoogle Scholar
• 107 Jordan A, Scholz R, Wust P et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int. J. Hyperthermia 13(6), 587–605 (1997).
  Medline CASGoogle Scholar
• 108 Jordan A, Scholz R, Wust P et al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J. Magn. Magn. Mater. 194, 185–196 (1999).
  CASGoogle Scholar
• 109 Johannsen M, Gneveckow U, Taymoorian K et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective Phase I trial. Int. J. Hyperthermia 23(3), 315–323 (2007).
  Medline CASGoogle Scholar
• 110 Johannsen M, Thiesen B, Wust P, Jordan A. Magnetic nanoparticle hyperthermia for prostate cancer. Int. J. Hyperthermia 26(8), 790–795 (2010).
  MedlineGoogle Scholar
• 111 ClinicalTrials.gov (2014). Magnetic nanoparticle thermoablation-retention and maintenance in the prostate: a Phase 0 study in men (MAGNABLATE I). https://clinicaltrials.gov/ct2/show/NCT02033447.
  Google Scholar
• 112 Bullivant JP, Zhao S, Willenberg BJ, Kozissnik B, Batich CD, Dobson J. Materials characterization of feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia. Int. J. Mol. Sci. 14(9), 17501–17510 (2013).
  MedlineGoogle Scholar
• 113 Balakrishnan VS, Rao M, Kausz AT et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur. J. Clin. Invest. 39(6), 489–496 (2009).
  Medline CASGoogle Scholar
• 114 Chen B, Li Y, Zhang X et al. An efficient synthesis of ferumoxytol induced by alternating-current magnetic field. Mater. Lett. 170, 93–96 (2016).
  CASGoogle Scholar
• 115 Helenek MJ, Tokars ML, Lawrence RP. Methods and compositions for administration of iron. US Patent 7754702 B2 (2010).
  Google Scholar
• 116 Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J. Blood Med. 3, 77–85 (2012).
  MedlineGoogle Scholar
• 117 Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJG. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4(2), 386–393 (2009).
  Medline CASGoogle Scholar
• 118 Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J. Magn. Reson. Imaging 41(4), 884–898 (2015).
  MedlineGoogle Scholar
• 119 ClinicalTrials.gov (2016). Using ferumoxytol-enhanced MRI to measure inflammation in patients with brain tumors or other conditions of the CNS. https://clinicaltrials.gov/ct2/show/NCT02452216.
  Google Scholar
• 120 ClinicalTrials.gov (2015). Ferumoxytol enhanced MRI for the detection of lymph node involvement in prostate cancer. https://clinicaltrials.gov/ct2/show/results/NCT01296139.
  Google Scholar
• 121 Singha N, Jenkinsa GJS, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 1, 5358 (2010).
  Google Scholar
• 122 Mahmoudi M, Hofmann H, Rothen-Rutishauser B, Petri-Fink A. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem. Rev. 112(4), 2323–2338 (2012).
  Medline CASGoogle Scholar
• 123 Feraheme (ferumoxytol) injection, prescribing information. AMAG Pharmaceuticals, Inc., MA, USA (2010). https://globenewswire.com/news-release/2017/08/03/1071940/0/en/AMAG-Completes-Feraheme-ferumoxytol-FDA-Submission-for-the-Treatment-of-All-Adult-Patients-With-Iron-Deficiency-Anemia.html.
  Google Scholar
• 124 Venditto VJ, Szoka FC Jr. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65, 80–88 (2013).
  Medline CASGoogle Scholar
• 125 Ma M, Zhang Y, Yu W, Shen H-Y, Zhang H-Q, Gu N. Preparation and characterization of magnetite nanoparticles coated by amino silane. Coll. Surf. A 212(2), 219–226 (2003).
  CASGoogle Scholar